Skip to main content

Eiger BioPharmaceuticals, Inc. (EIGR)

NASDAQ: EIGR · IEX Real-Time Price · USD
7.15 0.01 (0.07%)
Sep 23, 2021 10:34 AM EDT - Market open
Market Cap241.39M
Revenue (ttm)5.74M
Net Income (ttm)-24.41M
Shares Out33.93M
EPS (ttm)-0.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume21,280
Open7.15
Previous Close7.15
Day's Range7.15 - 7.25
52-Week Range6.80 - 13.49
Beta1.33
AnalystsStrong Buy
Price Target29.00 (+305.6%)
Est. Earnings DateNov 4, 2021

About EIGR

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the tre...

IndustryBiotechnology
CEODavid Cory
Employees35
Stock ExchangeNASDAQ
Ticker SymbolEIGR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for EIGR stock is "Strong Buy." The 12-month stock price forecast is 29.00, which is an increase of 305.59% from the latest price.

Price Target
$29.00
(305.59% upside)
Analyst Consensus: Strong Buy

News

Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief Compliance Officer

PALO ALTO, Calif., Sept. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted ...

2 days ago - PRNewsWire

Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOG...

PALO ALTO, Calif., Sept. 20, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted...

3 days ago - PRNewsWire

Eiger BioPharmaceuticals to Participate in Upcoming September 2021 Investor Conferences

PALO ALTO, Calif., Sept. 1, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted ...

3 weeks ago - PRNewsWire

Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -5.56% and 29.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted t...

1 month ago - PRNewsWire

Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism

PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted t...

1 month ago - PRNewsWire

Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences

PALO ALTO, Calif., Aug. 3, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted th...

1 month ago - PRNewsWire

Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thu...

PALO ALTO, Calif., July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted ...

2 months ago - PRNewsWire

Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

PALO ALTO, Calif., July 7, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted t...

2 months ago - PRNewsWire

Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly ...

PALO ALTO, Calif., July 6, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted th...

2 months ago - PRNewsWire

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PALO ALTO, Calif., July 2, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted t...

2 months ago - PRNewsWire

Eiger BioPharmaceuticals Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (...

PALO ALTO, Calif. , June 29, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted ...

2 months ago - PRNewsWire

Eiger Bio's Avexitide Reduces Glucose Infusion Requirements To Maintain Normal Glucose Levels In Neonates, Infants

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced an oral poster presentation of Phase 2 study results of Avexitide in congenital hyperinsulinism (HI) at the American Diabetes Association Scientific...

2 months ago - Benzinga

Eiger BioPharmaceuticals Announces Presentation of Positive Phase 2 Results of Avexitide in Congenital Hyperinsulinis...

PALO ALTO, Calif., June 28, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted ...

2 months ago - PRNewsWire

Eiger BioPharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted t...

3 months ago - PRNewsWire

Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

PALO ALTO, Calif., May 6, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted the...

4 months ago - PRNewsWire

Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study i...

PALO ALTO, Calif., May 3, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted the...

4 months ago - PRNewsWire

Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thur...

PALO ALTO, Calif., April 29, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted ...

4 months ago - PRNewsWire

Eiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim Sablich to its Board of Directors

PALO ALTO, Calif., April 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies...

5 months ago - PRNewsWire

Eiger BioPharmaceuticals (EIGR) Reports Q4 Loss, Lags Revenue Estimates

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -275.76% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

PALO ALTO, Calif., March 9, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of fou...

6 months ago - PRNewsWire

Eiger Bio's Avexitide Shows Reduced Rates Of Hypoglycemia, Rescue In Outpatient Setting

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announces that results from the Phase 2 PREVENT study of Avexitide in patients with severe Post-Bariatric Hypoglycemia (PBH) were published in the Journal of ...

6 months ago - Benzinga

Week 1 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge

Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year with avg ann...

8 months ago - Seeking Alpha

Eiger Looks Like A Solid Long-Term Play After Zokinvy's Approval

Eiger is solely focused on rare disease opportunities with its big target being hepatitis delta virus. Eiger's first therapy Zokinvy just got approved which nets the company an important Priority Review...

9 months ago - Seeking Alpha

Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford ...

PALO ALTO, Calif., Nov. 25, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare dise...

9 months ago - PRNewsWire